Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
Nephrology has benefited from conducting increasingly large high-quality trials in the last 5- 10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple pharmacotherapies that provide kidney and/or cardiovascular protection for certain typ...
المؤلفون الرئيسيون: | Zhu, D, Staplin, N, Haynes, R, Herrington, W, Judge, P |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Oxford University Press
2025
|
مواد مشابهة
-
Kidney disease trials for the 21st century: innovations in design and conduct
حسب: Herrington, W, وآخرون
منشور في: (2019) -
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
حسب: Mayne, K, وآخرون
منشور في: (2024) -
Renoprotective effect of pentoxifylline in advanced chronic kidney disease
حسب: Chih-Chin Kao
منشور في: (2015-01-01) -
Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
حسب: Preiss, D, وآخرون
منشور في: (2022) -
The prevention and management of chronic kidney disease among patients with metabolic syndrome
حسب: Zhu, D, وآخرون
منشور في: (2025)